25freespinsonregistrationnodeposit| Hutchison Pharmaceutical will release data at the American Society of Clinical Oncology Annual Meeting

Hehuang Pharmaceutical (001325freespinsonregistrationnodeposit.HK) announced25freespinsonregistrationnodepositThe latest and updated data from several studies of compounds independently developed by Hutchison Pharmaceutical will be announced next Friday (May 31) to June 4 at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, USA.

The company said that the results of a Phase II registration study conducted by fruquintinib in conjunction with sintimab in 98 patients with endometrial cancer with second-line pMMR(Mismatch Repair Complete) status or above will be announced at the conference. The study supports the submission of new drug marketing applications in China.

Following the preliminary data from the FRUTIGA Phase III study of fruquintinib for the second-line treatment of gastric cancer, which were released at the ASCO Plenary Series session held in February this year, further updated efficacy data for key subgroups of the study, as well as quality of life data, will be announced at this year's ASCO Annual Meeting. In addition, further data from the FRESCO and FRESCO-2 colorectal cancer phase III studies, sufantinib combination therapy in the treatment of small cell lung cancer, and preliminary clinical data on the ERK1/2 inhibitor HMPL-295 will also be announced at the conference.

Tags:

Prev: houseoffun200freespins2021| Sony Xperia Pro C exposure: 6.0-inch 2K screen +1-inch main camera sensor
Next: musicalbingonearme| Tesla Model S / X models launch a new "Moonlight Silver" car paint, optional for 25000 yuan